Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

Higher Naloxone Doses Narrowly Favored By FDA Panel
Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids
What's Driving Price Increases For Addiction Treatment Drugs?
Novartis’s Zykadia ASCENDs First-Line NSCLC Heights But Roche’s Alecensa Gives Chase
KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence
Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer
Celator Shines At ASCO, Highlights Upside For Jazz
ASCO Preview: Alecensa Bests Xalkori In Japan Head-To-Head
Opioid REMS: FDA Sees No Clear Verdict On Risk Management Program's Impact
Genentech’s Siegel: Why Not More Accelerated Approvals In Immunology?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts